The migraine treatment ‘Migapen Capsule’ has been newly renewed and released as ‘Migapen S Soft Capsule’.
‘Migapen’ is Ourdrug OTC's flagship product and has been consistently loved by consumers for over 30 years, establishing itself as the ‘national headache medicine’.
The newly released “Migapen S Soft Capsule” has been renewed with improved formulation and ingredients, and it is hoped that it will firmly establish itself as the ‘new migraine medicine’ by consumers.
The core of this renewal is the change to a liquid soft capsule formulation to greatly improve absorption rate, and the upgrade with ingredients proven for fast pain relief and sustained effect.
As part of the brand expansion strategy, in addition to ‘Migapen S Soft Capsule,’ two more products, ‘Migapen Eve Soft Capsule’ (pain reliever for women) and ‘Migapen Fresh Soft Capsule’ (broad-spectrum pain treatment and antipyretic), are planned to be additionally released.
‘Migapen S Soft Capsule’ is available at pharmacies, with Migapen Eve Soft Capsule scheduled for release at the end of April, and Migapen Fresh Soft Capsule in early June.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
